JP6170435B2 - 改変ノッチンペプチドを含む融合タンパク質及びその使用 - Google Patents

改変ノッチンペプチドを含む融合タンパク質及びその使用 Download PDF

Info

Publication number
JP6170435B2
JP6170435B2 JP2013537908A JP2013537908A JP6170435B2 JP 6170435 B2 JP6170435 B2 JP 6170435B2 JP 2013537908 A JP2013537908 A JP 2013537908A JP 2013537908 A JP2013537908 A JP 2013537908A JP 6170435 B2 JP6170435 B2 JP 6170435B2
Authority
JP
Japan
Prior art keywords
binding
receptor
axl
integrin
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013537908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014504270A5 (enExample
JP2014504270A (ja
Inventor
アール コクラン ジェニファー
アール コクラン ジェニファー
エス ジョーンズ ダグラス
エス ジョーンズ ダグラス
エス カリオリス ミハリス
エス カリオリス ミハリス
ピンーチュアン ツァイ
ピンーチュアン ツァイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2014504270A publication Critical patent/JP2014504270A/ja
Publication of JP2014504270A5 publication Critical patent/JP2014504270A5/ja
Application granted granted Critical
Publication of JP6170435B2 publication Critical patent/JP6170435B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Insects & Arthropods (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013537908A 2010-11-08 2011-11-07 改変ノッチンペプチドを含む融合タンパク質及びその使用 Active JP6170435B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41135010P 2010-11-08 2010-11-08
US61/411,350 2010-11-08
PCT/US2011/059599 WO2012064658A1 (en) 2010-11-08 2011-11-07 Fusion proteins comprising an engineered knottin peptide and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017079525A Division JP6535361B2 (ja) 2010-11-08 2017-04-13 改変ノッチンペプチドを含む融合タンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2014504270A JP2014504270A (ja) 2014-02-20
JP2014504270A5 JP2014504270A5 (enExample) 2014-12-25
JP6170435B2 true JP6170435B2 (ja) 2017-07-26

Family

ID=46051256

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013537908A Active JP6170435B2 (ja) 2010-11-08 2011-11-07 改変ノッチンペプチドを含む融合タンパク質及びその使用
JP2017079525A Active JP6535361B2 (ja) 2010-11-08 2017-04-13 改変ノッチンペプチドを含む融合タンパク質及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017079525A Active JP6535361B2 (ja) 2010-11-08 2017-04-13 改変ノッチンペプチドを含む融合タンパク質及びその使用

Country Status (7)

Country Link
US (3) US10844106B2 (enExample)
EP (2) EP3604549A1 (enExample)
JP (2) JP6170435B2 (enExample)
AU (3) AU2011326164B2 (enExample)
CA (1) CA2817197C (enExample)
DK (1) DK2638173T3 (enExample)
WO (1) WO2012064658A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008045252A2 (en) * 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
DK2638173T3 (da) 2010-11-08 2019-09-30 Univ Leland Stanford Junior Fusionsproteiner omfattende et manipuleret knottin-peptid og anvendelser deraf
WO2013078250A2 (en) 2011-11-22 2013-05-30 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides that bind alpha-v-beta-6 integrin
WO2013177187A2 (en) 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
WO2014063012A1 (en) 2012-10-19 2014-04-24 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
CN105189540A (zh) 2012-12-10 2015-12-23 弗莱德哈钦森癌症研究中心 含脂质运载蛋白融合伴侣
ES2665323T7 (es) * 2012-12-14 2023-06-15 Univ Leland Stanford Junior Péptidos de AXL modificados y su uso en la inhibición de la señalización de AXL en terapia anti-metastásica
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
US11013814B2 (en) 2017-03-16 2021-05-25 Blaze Bioscience, Inc. Cartilage-homing peptide conjugates and methods of use thereof
EP3180018B1 (en) * 2014-08-12 2019-07-24 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
US20170216403A1 (en) 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
EP3313427A4 (en) * 2015-06-26 2018-12-26 Fred Hutchinson Cancer Research Center Therapeutic peptides and methods of use thereof
JP6966424B2 (ja) 2015-09-09 2021-11-17 フレッド ハッチンソン キャンサー リサーチ センター 軟骨ホーミングペプチド
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
JP7308505B2 (ja) * 2016-01-08 2023-07-14 マキシオン セラピューティクス リミテッド 多様性を変化させた足場ドメインを有する結合メンバー
US10888603B2 (en) * 2016-02-12 2021-01-12 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cancer cells expressing tumor-associated integrins
US10765625B2 (en) 2016-03-15 2020-09-08 The Board Of Trustees Of The Leland Stanford Junior University Knottin-drug conjugates and methods of using the same
WO2018044234A1 (en) * 2016-08-31 2018-03-08 Nanyang Technological University Cysteine-rich polypeptides and conjugates and methods of using the same
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
US10603358B2 (en) 2017-01-10 2020-03-31 Nodus Therapeutics Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
US11548923B2 (en) 2017-01-18 2023-01-10 Fred Hutchinson Cancer Center Peptide compositions and methods of use thereof for disrupting TEAD interactions
EP3638290A4 (en) 2017-06-15 2021-04-07 Blaze Bioscience, Inc. KIDNEY HOMING PEPTIDE CONJUGATES AND METHOD OF USING THEREOF
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
JP7221545B2 (ja) 2017-07-24 2023-02-14 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー ホスファチジルセリン標的化融合分子およびそれらの使用方法
AU2018388583A1 (en) 2017-12-19 2020-06-11 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
US11235032B2 (en) 2019-01-23 2022-02-01 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
CN113661240B (zh) * 2019-04-02 2024-11-05 伊莱利利公司 选择和检测结合肽的方法
JP2022531191A (ja) * 2019-04-29 2022-07-06 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 肝細胞増殖因子の操作された二量体断片を使用する眼の治療方法
SG11202112129SA (en) * 2019-05-22 2021-11-29 Univ Leland Stanford Junior Drug conjugates and methods of using same
AU2020357806A1 (en) * 2019-09-30 2022-05-26 The Board Of Trustees Of The Leland Stanford Junior University Knottin-immunostimulant conjugates and related compositions and methods
US20230211001A1 (en) * 2020-07-30 2023-07-06 The Board Of Trustees Of The Leland Stanford Junior University Lysosomal Targeting Molecules Comprising Knottin Peptides And Related Compositions And Methods
MX2020012914A (es) * 2020-11-27 2022-05-30 Centro De Investig Cientifica Y De Educacion Superior De Ensenada Baja California Cicese Proteina andamio para la generacion de proteinas quimericas de union a antigeno.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468634A (en) 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6303749B1 (en) * 1999-01-29 2001-10-16 Amgen Inc. Agouti and agouti-related peptide analogs
DE10053224A1 (de) * 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
EP1358211A2 (en) 2001-01-31 2003-11-05 Mount Sinai Hospital Methods for regulating the kinase domain of ephb2
GB0110430D0 (en) 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
NZ548828A (en) 2004-01-20 2009-07-31 Merus B V Mixtures of binding proteins
US20060040325A1 (en) * 2004-08-16 2006-02-23 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytoxicity activity
US7674881B2 (en) 2005-10-07 2010-03-09 The University Of Chicago Convergent synthesis of proteins by kinetically controlled ligation
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
EP2170395A1 (en) * 2007-07-02 2010-04-07 Wyeth LLC Modulators of axl for use in treating bone disorders
CA2694488A1 (en) * 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
WO2009097017A2 (en) * 2007-09-18 2009-08-06 The Jackson Laboratory Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
US8906356B2 (en) * 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
WO2010048588A2 (en) 2008-10-23 2010-04-29 Massachusetts Institute Of Technology Directed engagement of activating fc receptors
US8329826B2 (en) 2008-11-06 2012-12-11 The Board Of Trustees Of The Leland Stanford Junior University Surface modification of interpenetrating polymer networks
US8778888B2 (en) 2009-11-06 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
JP5965322B2 (ja) 2010-01-22 2016-08-03 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗転移療法におけるａｘｌシグナル伝達の阻害
DK2638173T3 (da) * 2010-11-08 2019-09-30 Univ Leland Stanford Junior Fusionsproteiner omfattende et manipuleret knottin-peptid og anvendelser deraf
US10350266B2 (en) * 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein

Also Published As

Publication number Publication date
CA2817197C (en) 2020-08-04
JP2017160222A (ja) 2017-09-14
WO2012064658A1 (en) 2012-05-18
US12240882B2 (en) 2025-03-04
US20230227523A1 (en) 2023-07-20
US11498952B2 (en) 2022-11-15
EP2638173B1 (en) 2019-06-19
AU2011326164B2 (en) 2016-05-05
AU2016210712B2 (en) 2017-10-26
EP3604549A1 (en) 2020-02-05
US20140073518A1 (en) 2014-03-13
US20210206824A1 (en) 2021-07-08
EP2638173A4 (en) 2014-03-26
US10844106B2 (en) 2020-11-24
CA2817197A1 (en) 2012-05-18
AU2016210712A1 (en) 2016-09-08
JP2014504270A (ja) 2014-02-20
JP6535361B2 (ja) 2019-06-26
AU2018200587B2 (en) 2019-12-12
EP2638173A1 (en) 2013-09-18
AU2011326164A1 (en) 2013-05-30
DK2638173T3 (da) 2019-09-30
AU2018200587A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
JP6170435B2 (ja) 改変ノッチンペプチドを含む融合タンパク質及びその使用
JP6783797B2 (ja) 抗がん融合ポリペプチド
JP6041799B2 (ja) Ｔｒａｉｌｒ２特異的多量体足場
JP6486908B2 (ja) 肝細胞増殖因子に結合する設計アンキリン反復タンパク質
KR101151805B1 (ko) 바이포달 펩타이드 바인더
AU2014301777B2 (en) High-stability T-cell receptor and preparation method and application thereof
US20090131317A1 (en) Compounds and peptides that bind the trail receptor
TR201906295T4 (tr) IL-4 R alfaya bağlanan gözyaşı lipokalini muteinleri.
US20100093624A1 (en) Peptide therapeutics that bind vegf and methods of use thereof
TW201107471A (en) Polypeptides selective for αvβ3 integrin conjugated with a variant of human serum albumin (HSA) and pharmaceutical uses thereof
JP6717725B2 (ja) 遺伝子操作した成長因子変異体
KR102717638B1 (ko) 뉴레귤린-4 화합물 및 사용 방법
CN108367048A (zh) 用于组织修复的双特异性治疗性蛋白质
KR102150419B1 (ko) Pd-l1에 결합하는 펩타이드 및 이의 용도
JP2023532293A (ja) 抗ｎｍｅ抗体および癌または癌転移の治療方法
KR20120125455A (ko) 세포내 타겟 결합용 바이포달 펩타이드 바인더
KR101263424B1 (ko) 세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물
WO2018109771A1 (en) Fusion proteins for treatment of cancer
CN115991780A (zh) 一种抗人血小板胶原蛋白受体gp-vi抗体或其抗原结合片段及其应用
HK40064429B (zh) 抗nme抗体及治疗癌症或癌症转移的方法
HK1087418B (en) Fusion polypeptides, and use thereof in antivascular tumor therapy
HK1087418A1 (en) Fusion polypeptides, and use thereof in antivascular tumor therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170413

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170420

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170606

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170630

R150 Certificate of patent or registration of utility model

Ref document number: 6170435

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250